For years, the biggest complaint about GLP-1 drugs has been simple: nobody likes needles. Foundayo (orforglipron) is Eli Lilly's answer to that — a once-daily pill that works through the same core mechanism as semaglutide (Ozempic, Wegovy), but you just swallow it. No injections, no refrigeration, no food restrictions. It's now FDA-approved and is the first oral GLP-1 approved specifically for weight loss in the US without any food or water restrictions.
The FDA approved Foundayo on April 1, 2026. This page covers what you need to know based on the approved label, the Phase 3 trial data, and Lilly's pricing and availability details.
Important: This page is for informational purposes only and is not medical advice. Always follow your prescriber's instructions.
Foundayo is a GLP-1 receptor agonist — the same basic mechanism as semaglutide. It binds to GLP-1 receptors in your brain and gut, suppressing appetite, slowing digestion, and helping regulate blood sugar. If you're familiar with how Wegovy or Ozempic works, you already understand most of what Foundayo does.
The key difference is how it's made. Semaglutide and tirzepatide are peptides — large, complex molecules that have to be injected because stomach acid would destroy them before they could be absorbed. Foundayo is a small molecule, which means it's more like a traditional drug in pill form. Your gut can absorb it intact.
A few practical advantages that come from this:
What it is not: a dual agonist. Tirzepatide hits both GLP-1 and GIP receptors, which is why it tends to produce stronger weight loss results. Foundayo is GLP-1 only, so it's more comparable to semaglutide than to tirzepatide in terms of mechanism.
The approved label uses different dose strengths than what was tested in the Phase 3 trials — the commercial formulation is reformulated at lower milligram strengths. The titration schedule below is what's on the actual Foundayo label:
| Dose | Notes |
|---|---|
| 0.8 mg | Starting dose |
| 2.5 mg | Increase after at least 30 days on previous dose |
| 5.5 mg | Increase after at least 30 days on previous dose |
| 9 mg | Optional increase after at least 30 days |
| 14.5 mg | Optional increase after at least 30 days |
| 17.2 mg | Maximum dose; optional increase after at least 30 days |
Once daily, tablets swallowed whole. Take with or without food, at any time of day.
A few things worth noting:
This is the honest answer most people want: Foundayo is less effective for weight loss than the leading injectables, but it closes the gap meaningfully — and it's a pill.
| Metric | Foundayo | Semaglutide 2.4 mg (Wegovy) | Tirzepatide 15 mg (Zepbound) |
|---|---|---|---|
| Route | Daily pill | Weekly injection | Weekly injection |
| Weight loss (trial avg.) | ~11–12% body weight | ~15% body weight | ~20% body weight |
| Duration | 72 weeks | 68 weeks | 72 weeks |
| Mechanism | GLP-1 only | GLP-1 only | GLP-1 + GIP dual agonist |
| Nausea rate | 13–16% | ~44% | ~18–33% |
| Discontinuation (side effects) | 5–10% | ~5–7% | ~4–7% |
The ~11–12% weight loss figure comes from the ATTAIN-1 trial at the highest dose: 12.4% among completers, 11.1% on an intent-to-treat basis (about 27 lbs and 25 lbs respectively).
What this means practically:
One surprisingly interesting data point: The ATTAIN-MAINTAIN trial specifically looked at people who switched from injectable GLP-1s to Foundayo. People who switched from Wegovy maintained about 95% of their prior weight loss. People who switched from Zepbound maintained about 80%. So if you're stabilized on an injectable and switch to the pill, you're likely to hold most of your progress — you're not starting from scratch.
The approved label lists the most common side effects as: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, abdominal bloating, fatigue, belching, heartburn, gas, and hair loss.
A few things worth knowing about the profile:
The label also includes serious risks to be aware of: pancreatitis, severe GI problems, dehydration-related kidney issues, hypoglycemia (particularly relevant if you're also on diabetes medications), allergic reactions, vision changes, and gallbladder complications. These are serious but uncommon — the same category of risks that apply to GLP-1s generally.
The FDA approved Foundayo on April 1, 2026 — 50 days after Lilly's filing, making it the fastest New Molecular Entity approval since 2002. It was approved under the Commissioner's National Priority Voucher (CNPV) pilot program, which is designed to fast-track medicines addressing significant unmet medical need. No Advisory Committee meeting was required, which is generally read as the FDA finding the safety and efficacy data clean and straightforward.
Foundayo is approved for adults with obesity (BMI ≥ 30), or adults who are overweight (BMI ≥ 27) with at least one weight-related comorbid condition.
Pricing:
For context, that's competitive with what injectable GLP-1s cost through similar programs — and significantly below the $1,000+ list prices for Wegovy and Zepbound without insurance.
Availability:
LillyDirect started accepting prescriptions immediately following approval, with first shipments going out April 6, 2026. Broad retail pharmacy and telehealth availability is expected shortly after. Lilly reportedly stockpiled $1.5 billion of inventory ahead of the launch specifically to avoid the supply shortages that plagued semaglutide and tirzepatide in 2023–2024.
This is the practical question for a lot of people on this site.
First: Foundayo is almost certainly not compoundable. It's a patented small molecule, not a peptide. Compounding pharmacies have made compounded semaglutide and tirzepatide available partly because the FDA's shortage list created a legal pathway. Foundayo isn't on any shortage list, it's not a peptide, and Lilly has clearly planned for adequate supply. There is no realistic compounding pathway here.
Second: it's not a replacement for compounded tirzepatide. If you're getting 15–20% weight loss on tirzepatide, switching to Foundayo would likely mean accepting meaningfully less weight loss (11–12%). Plus you lose the GIP agonist effect. If tirzepatide is working well for you, this isn't an upgrade or even a lateral move.
Where Foundayo could make sense:
On cost vs. compounded: Compounded semaglutide and tirzepatide are typically $100–$200/month from telehealth providers, often less. Foundayo at $149–$349/month is more expensive than most compounded options — but the $25/month insurance savings card rate makes it genuinely accessible for people with commercial coverage.
If you want to compare your current semaglutide dosing to what Foundayo might mean for you, the Semaglutide Calculator can help you think through your current protocol. For tirzepatide context, the Tirzepatide Dose Calculator is the place to start.
This page was updated April 2026 following FDA approval of Foundayo (orforglipron). Information is based on the approved label, published Phase 3 trial data, and publicly available information from Eli Lilly. Nothing here is medical advice — talk to your prescriber about what's right for you.